CONFIRM trial: what is the real efficacy of second-line immunotherapy in mesothelioma?

Affiliations

¹ Medical Oncology Unit, Grand Metropolitan Hospital "Bianchi-Melacrino-Morelli", Reggio Calabria, Italy; Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA, USA.
² Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori, IRCCS, Fondazione G Pascale, Naples, Italy.
³ Department of Precision Oncology, University Hospital of Campania "L Vanvitelli", Naples 80138, Italy. Electronic address: valerio.nardone@unicampania.it.
⁴ Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA, USA; Department of Medical Biotechnologies, University of Siena, Siena, Italy.
⁵ Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA, USA; Italian Group for Research and Therapy for Mesothelioma (GIMe), Voghera, Italy.

Comment

Pierpaolo Correale et al. Lancet Oncol. 2022 Jan.

. 2022 Jan;23(1):e13.

doi: 10.1016/S1470-2045(21)00702-6.

¹ Medical Oncology Unit, Grand Metropolitan Hospital "Bianchi-Melacrino-Morelli", Reggio Calabria, Italy; Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA, USA.
² Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori, IRCCS, Fondazione G Pascale, Naples, Italy.
³ Department of Precision Oncology, University Hospital of Campania "L Vanvitelli", Naples 80138, Italy. Electronic address: valerio.nardone@unicampania.it.
⁴ Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA, USA; Department of Medical Biotechnologies, University of Siena, Siena, Italy.
⁵ Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA, USA; Italian Group for Research and Therapy for Mesothelioma (GIMe), Voghera, Italy.

No abstract available

Conflict of interest statement

We declare no competing interests.

Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial.
Fennell DA, Ewings S, Ottensmeier C, Califano R, Hanna GG, Hill K, Danson S, Steele N, Nye M, Johnson L, Lord J, Middleton C, Szlosarek P, Chan S, Gaba A, Darlison L, Wells-Jordan P, Richards C, Poile C, Lester JF, Griffiths G; CONFIRM trial investigators. Fennell DA, et al. Lancet Oncol. 2021 Nov;22(11):1530-1540. doi: 10.1016/S1470-2045(21)00471-X. Epub 2021 Oct 14. Lancet Oncol. 2021. PMID: 34656227 Free PMC article. Clinical Trial.
CONFIRM trial: what is the real efficacy of second-line immunotherapy in mesothelioma? - Authors' reply.
Fennell DA, Griffiths G, Ottensmeier C, Hanna GG, Danson S, Szlosarek P, Nye M. Fennell DA, et al. Lancet Oncol. 2022 Jan;23(1):e14-e15. doi: 10.1016/S1470-2045(21)00722-1. Lancet Oncol. 2022. PMID: 34973224 No abstract available.